ZOC2017217 for Age-Related Cataract
This study is testing an investigational eye drop called ZOC2017217 for people with age-related cataracts. It's a pilot study, meaning it's an early look at how well ZOC2017217 works and if it's safe. About 40 people aged 50 and older will participate. You would use either ZOC2017217 or a placebo (an inactive substance) in both eyes twice a day for 24 weeks. Researchers will measure your vision (Best Corrected Distance Visual Acuity or BCDVA), how well you see in low light (contrast sensitivity), and your overall vision-related quality of life (Visual Function Questionnaire or VFQ-25) to see if ZOC2017217 helps. The study's current status is unclear.
- Study design
- This is a randomized, double-masked (neither you nor your doctor will know if you're getting the active drug or placebo), placebo-controlled pilot study involving about 40 participants.
- What's involved
- You would administer eye drops twice a day for 24 weeks. Your vision will be checked at the start, and at weeks 4, 12, and 24.
- Compensation
- Not stated in the trial record.
- Follow-up
- After 24 weeks of treatment, participants with new or ongoing eye-related side effects will have a safety follow-up evaluation 2 weeks later.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract
At a glance
Conditions
Where it's being run
21 sites across 12 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- BCDVABaseline as compared to Weeks 4, 12, and 24.
Change from baseline in BCDVA at Weeks 4, 12, and 24.
- Contrast SensitivityBaseline as compared to Weeks 4, 12, and 24.
Change from baseline in contrast sensitivity at Weeks 4, 12, and 24.
- Visual Function Questionnaire (VFQ-25)Baseline compared to Weeks 4, 12, and 24.
Change from baseline in Visual Function Questionnaire (VFQ-25) scores at Weeks 4, 12, and 24. VFQ-25 score total should increase from the baseline visit to show better visual function at Weeks 4, 12, and 24.
- Crystalline Lens OpacityBaseline compared to Weeks 4, 12, and 24.
Change from baseline in crystalline lens opacity at Weeks 4, 12, and 24.
- BCDVABaseline compared to Weeks 4, 12, and 24.
Proportion of subjects gaining ≥5, ≥10, or ≥15 letters from baseline in BCDVA at Weeks 4, 12, and 24.
- BCDVABaseline compared to Weeks 4, 12, and 24.
Proportion of subjects losing ≤5, ≤10, or ≤15 letters from baseline in BCDVA at Weeks 4, 12, and 24.
- BCDVABaseline compared to Weeks 4, 12, and 24.
Proportion of subjects achieving BCDVA ≥0.3, 0.1, or 0.0 Logarithm of the Minimum Angle of Resolution (LogMAR; Snellen: 20/40, 20/25, or 20/20) at Weeks 4, 12, and 24.